Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine. The new…
AstraZeneca has reportedly tanked a deal that would have taken high-profile rare disease company Sobi private over fears its respiratory drugs would fall into the hands of rivals. The Big Pharma…
The prostate cancer-focused technology’s FDA clearance comes just a month after Insightec racked up yet another regulatory approval for its Exablate Neuro system.
In studies submitted to the FDA for authorization, Sound’s software was used to monitor patients with chronic respiratory pulmonary disease, asthma, congestive heart failure, anxiety and more.
The BeyondSpring roller coaster has plunged downward again. While BeyondSpring wowed investors with its phase 3 lung cancer data in August, the FDA found less to like in another indication, rejecting…
In one of the biggest funding rounds for a European biotech ever, Czech Republic cancer company Sotio Biotech has grabbed a huge 280 million euro ($316 million) raise.
CAR-T cells to treat cancer have precious little time to proliferate in the body, which often limits their anti-tumor efficacy. A team at the Curie Institute pinpointed the protein SOCS1 as an…
GlaxoSmithKline poached Pfizer’s RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it’s lost many research staffers this past year. Parthenon Therapeutics…
Health IT, MedCity Influencers Building a modern and equitable public health system By Kristen Ballantine There are many lessons to be learned from the Covid-19 pandemic, but perhaps the biggest is the need for proactive, long-term, and sustained investments in our public health system. MedCity Influencers Amid Covid-19, a longstanding coordination-of-benefits issue pressures state Medicaid …
AviadoBio has come flying out the traps surrounded by A-list names. Incubated at F-Prime Capital and Johnson & Johnson’s JJDC, AviadoBio exited stealth with $80 million from backers such as New…
